Biofrontera, Inc. (NASDAQ: BFRI) is engaged as a biopharmaceutical company, which is focused on the research, development, testing and commercialization of dermatological treatment. Shares of the company are rallying 36% through early trading on Thursday, December 2, 2021. Over the past three months, Biofrontera has seen average daily volume of 19.57 million shares. However, volume of 29.93 million shares or dollar volume of around $169.4 million, has already exchanged hands through early trading on Thursday.
Shares of Biofrontera are gaining after the company announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the company’s patent application, titled “Illumination for Photodynamic Therapy.” The patent covers a innovative, pain-reducing illumination protocol for photodynamic therapy (PDT).
The dynamic and innovative illumination protocol features changing intensities of lighting combined in a pre-determined order with interruptions of illumination to help reduce pain perception to patients. Biofrontera’s new illumination protocol seeks to become the new standard-of-care to treat PDT by combining Ameluz with BF-RhodoLED to help modulate light for pain reduction.
Starting in 2022, Biofrontera plans to launch Phase 3 clinical trials for the treatment of actinic keratoses on the face and scalp. The trial will test the use of three tubes of Ameluz and RhodoLED XL lamps.
“This patented illumination protocol demonstrates Biofrontera’s commitment to the patients’ need for innovative treatments. The patent also strengthens Biofrontera’s competitiveness for our FDA-approved combination product, Ameluz® together with our PDT-lamp BF-RhodoLED® and its successor model RhodoLED® XL in the U.S. by providing an opportunity to pursue label expansion to include more patient-friendly protocols,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc.
Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.